Literature DB >> 22422739

Ambulatory care connections of Medicaid-insured children with sickle cell disease.

David G Bundy1, John Muschelli, Gwendolyn D Clemens, John J Strouse, Richard E Thompson, James F Casella, Marlene R Miller.   

Abstract

BACKGROUND: Sickle cell disease (SCD) requires coordinated ambulatory care from generalists and hematologists. We examined when children with SCD establish ambulatory care connections, whether these connections are maintained, and how these connections are used before and after hospitalizations. PROCEDURE: We conducted a retrospective cohort study of Medicaid-insured Maryland children with SCD from 2002 to 2008. For children enrolled from birth, time to first, second, and third generalist and first hematologist visits was plotted. For all children, we analyzed ambulatory visits by age group, by emergency department (ED) and hospital use, and before and after hospitalizations.
RESULTS: The overall study cohort comprised 851 children; 178 provided data from birth. Ambulatory care connections to generalists were made rapidly; connections to hematologists occurred more slowly, if at all (38% of children had not seen a hematologist by age 2 years). Visits with generalists decreased as patients aged, as did visits with hematologists (54% of children in the 12-17 year age group had no hematology visits in 2 years). Children with higher numbers of ED visits or hospitalizations also had higher numbers of ambulatory visits (generalist and hematologist). Most children had visits with neither generalists nor hematologists in the 30 days before and after hospitalizations.
CONCLUSIONS: Medicaid-insured children with SCD rapidly connect with generalists after birth; connections to hematologists occur more slowly. The observation that connections to generalists and hematologists diminish with time and are infrequently used around hospitalizations suggests that the ambulatory care of many Medicaid-insured children with SCD may be inadequate.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22422739     DOI: 10.1002/pbc.24129

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  7 in total

1.  Association between Hospital Volume and Within-Hospital Intensive Care Unit Transfer for Sickle Cell Disease in Children's Hospitals.

Authors:  Jean L Raphael; Troy Richardson; Matt Hall; Suzette O Oyeku; David G Bundy; Ram V Kalpatthi; Samir S Shah; Angela M Ellison
Journal:  J Pediatr       Date:  2015-10-23       Impact factor: 4.406

2.  Care Coordination for Children With Sickle Cell Disease: A Longitudinal Study of Parent Perspectives and Acute Care Utilization.

Authors:  Tiffany L Rattler; Annette M Walder; Hua Feng; Jean L Raphael
Journal:  Am J Prev Med       Date:  2016-07       Impact factor: 5.043

3.  Barriers to care and quality of primary care services in children with sickle cell disease.

Authors:  Eufemia Jacob; Courtney Childress; Joana Duran Nathanson
Journal:  J Adv Nurs       Date:  2015-09-15       Impact factor: 3.187

4.  Preventive Care Delivery to Young Children With Sickle Cell Disease.

Authors:  David G Bundy; John Muschelli; Gwendolyn D Clemens; John J Strouse; Richard E Thompson; James F Casella; Marlene R Miller
Journal:  J Pediatr Hematol Oncol       Date:  2016-05       Impact factor: 1.289

5.  A feasibility study of telemedicine for paediatric sickle cell patients living in a rural medically underserved area.

Authors:  Seethal A Jacob; Aaron E Carroll; William E Bennett
Journal:  J Telemed Telecare       Date:  2019-11-06       Impact factor: 6.184

6.  CDC Grand Rounds: Improving the Lives of Persons with Sickle Cell Disease.

Authors:  Mary Hulihan; Kathryn L Hassell; Jean L Raphael; Kim Smith-Whitley; Phoebe Thorpe
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-11-24       Impact factor: 17.586

Review 7.  Administrative data identify sickle cell disease: A critical review of approaches in U.S. health services research.

Authors:  Scott D Grosse; Nancy S Green; Sarah L Reeves
Journal:  Pediatr Blood Cancer       Date:  2020-09-17       Impact factor: 3.838

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.